Abstracts Archive - Page 1439 of 2607 - ACR Meeting Abstracts

Abstract Number: 776 • 2017 ACR/ARHP Annual Meeting
Circulating Fibrocytes in Systemic Sclerosis Patients and Healthy Subjects: An in Vitro Study
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano², Amelia Chiara Trombetta³, Paola Contini⁴, Vanessa Smith⁵, Barbara Ruaro², Alberto Sulli³ and Renata Brizzolara², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ⁴Division of Clinical Immunology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ⁵Faculty of Internal Medicine, Ghent University, Ghent, Belgium
Background/Purpose: Circulating fibrocytes seem to exert immunomodulatory effects, expressing class II major histocompatability complex molecules (HLA-DP, -DQ, and -DR) and could have a role in…
Abstract Number: 777 • 2017 ACR/ARHP Annual Meeting
Differences between Temporal Artery Biopsy-Positive and Biopsy-Negative Giant Cell Arteritis: A Comparative Cohort Study
Matthew J. Koster¹, Karthik Yeruva¹, Cynthia S. Crowson² and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in patients aged 50 years or older. The presence of cranial features and an…
Abstract Number: 778 • 2017 ACR/ARHP Annual Meeting
Safety Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations
Sara Gale¹, Sophie Dimonaco², Huong Trinh¹, Katie Tuckwell², Neil Collinson², John H. Stone³, Khaled Sarsour¹, Jinglan Pei⁴, Jennifer H. Best¹, Christine Birchwood⁴ and Shalini Mohan¹, ¹Genentech, South San Francisco, CA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Recent clinical trial findings have shown efficacy for tocilizumab (TCZ) in treating giant cell arteritis (GCA).1,2 TCZ was approved for the treatment of GCA…
Abstract Number: 779 • 2017 ACR/ARHP Annual Meeting
Assessment of Treatment Response By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Large Vessel Vasculitis (LVV)
Shubhasree Banerjee¹, Sara Alehashemi², Ali Cahid Civelek³, Elaine Novakovich⁴, Armin Bagheri⁵, Ashkan Malayeri³, Mark Ahlman³ and Peter C. Grayson⁶, ¹Fellowship and training branch, NIAMS/NIH, Bethesda, MD, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁴Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD, ⁵Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, ⁶Research, National Institutes of Health, Bethesda, MD
Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serological (ESR, CRP) parameters. Imaging assessment, including FDG-PET, may also be…
Abstract Number: 780 • 2017 ACR/ARHP Annual Meeting
Short and Long-Term Follow-up with Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 49 Patients of Clinical Practice
Lucia C. Domínguez-Casas¹, Javier Loricera¹, Jose L. Hernández², Santos Castañeda³, Vicente Aldasoro⁴, María Varela-García⁵, Rosario Ibañez-Bosch⁵, Antonio Mera⁶, Eva Pérez-Pampin⁶, Alicia Humbría⁷, Jaime Calvo-Alén⁸, Elena Aurrecoechea⁹, Javier Narváez¹⁰, Amalia Sánchez-Andrade¹¹, Paloma Vela¹², Elvira Diez Alvarez¹³, Clara Moriano¹⁴, Cristina Mata¹⁵, Pau Lluch¹⁶, Concepción Moll¹⁷, Íñigo Hernández-Rodríguez¹⁸, Vanesa Calvo-Río¹, José Andrés Román-Ivorra¹⁹, Carlos Vazquez²⁰, Alfonso Corrales¹, MC Gonzalez-Vela²¹, Francisco Ortiz-Sanjuán²², Belén Atienza-Mateo¹, José Luis Martín-Varillas¹, Miguel Angel González-Gay²³ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁴Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁵Rheumatology, Complejo Hospitalario de Navarra. Navarra. Spain, Navarra, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, ⁷Rheumatology, Hospital Universitario La Princesa. IIS-IP. Madrid. Spain, Madrid, Spain, ⁸Rheumatology, Hospital de Sierrallana. Torrelavega. Cantabria. Spain, Alava, Spain, ⁹Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, ¹⁰Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ¹¹Hospital Universitario Lucus Augusti. Lugo. Spain, Lugo, Spain, ¹²Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ¹³Complejo Asistencial Universitario de León. León. Spain, León, Spain, ¹⁴Rheumatology, Complejo Asistencial Universitario de León. León. Spain, Leon, Spain, ¹⁵Rheumatology, Hospital de Laredo. Laredo. Spain, Laredo, Spain, ¹⁶Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ¹⁷Rheumatology., Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ¹⁸Rheumatology, CHUVI Vigo. Galicia. Spain, Vigo, Spain, ¹⁹Rheumatology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ²⁰Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ²¹Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²²Rheumatology., Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, ²³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa
Background/Purpose: Randomized clinical trial has shown the efficacy of tocilizumab (TCZ) in Giant cell arteritis (GCA). However this data are of selected cases of clinical…
Abstract Number: 781 • 2017 ACR/ARHP Annual Meeting
A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis
Valentin S. Schäfer¹, Stavros Chrysidis², Christian Dejaco³, Christina Duftner⁴, Annamaria Iagnocco⁵, George A. W. Bruyn⁶, Greta Carrara⁷, MA D'Agostino⁸, Eugenio De Miguel⁹, Andreas P Diamantopoulos¹⁰, Ulrich Fredberg¹¹, Wolfgang Hartung¹², Alojzija Hočevar¹³, Tanaz A. Kermani¹⁴, Matthew J. Koster¹⁵, Tove Lorenzen¹⁶, Pierluigi Macchioni¹⁷, Marcin Milchert¹⁸, Uffe Møller Døhn¹⁹, Chetan Mukhtyar²⁰, Cristina Ponte²¹, Sofia Ramiro²², Carlo Alberto Scirè²³, Lene Terslev²⁴, Kenneth J. Warrington¹⁵, Bhaskar Dasgupta²⁵ and Wolfgang A. Schmidt²⁶, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ³Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁵Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy, ⁶Rheumatology, MC Groep, Loenga, Netherlands, ⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ⁸Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁹Medicine, Universidad Autonoma Madrid, MADRID, Spain, ¹⁰Martina Hansens Hospital, Bærum, Oslo, Norway, ¹¹Diagnostic Centre, Silkeborg Regional Hospital, 8600 Silkeborg, Denmark, ¹²Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany, ¹³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Rheumatology, University of California Los Angeles, Los Angeles, CA, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ¹⁷Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ¹⁸Pomeranian Medical University, Szczecin,, Szczecin, Poland, ¹⁹Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ²⁰Norfolk and Norwich University Hospital, Norwich, United Kingdom, ²¹Rheumatology Department, Hospital de Santa Maria - Centro Hospital Lisboa Norte, Lisbon, Portugal, ²²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²³Italian Society for Rheumatology, Milan, Italy, ²⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ²⁵Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ²⁶Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: To test the reliability of recently established consensus-based ultrasound definitions for normal and vasculitic temporal and axillary arteries in patients with giant cell arteritis…
Abstract Number: 782 • 2017 ACR/ARHP Annual Meeting
Serum IL-6, SAA and Calprotectin As Biomarkers in Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen, Marjolein Hoekstra, Johan Bijzet, Wayel H. Abdulahad, Annemieke M.H. Boots and Elisabeth Brouwer, Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: GCA and PMR are closely related inflammatory diseases. The diagnostic criteria of both disorders depend on a combination of clinical features and elevated ESR…
Abstract Number: 783 • 2017 ACR/ARHP Annual Meeting
European League Against Rheumatisms Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice
Christian Dejaco¹, Sofia Ramiro², Christina Duftner³, Florent L. Besson⁴, Thorsten Bley⁵, Daniel Blockmans⁶, Elisabeth Brouwer⁷, Marco A. Cimmino⁸, Eric Clark⁹, Bhaskar Dasgupta¹⁰, Andreas P Diamantopoulos¹¹, Haner Direskeneli¹², Annamaria Iagnocco¹³, Thorsten Klink⁵, Lorna Neill¹⁴, Cristina Ponte¹⁵, Carlo Salvarani¹⁶, Riemer Slart¹⁷, Madeline Whitlock¹⁸ and Wolfgang A. Schmidt¹⁹, ¹Rheumatology, Hospital of Bruneck, Bruneck, Italy, ²Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁴Department of Nuclear Medicine, CHU Bicêtre, AP-HP, Université Paris-Sud, Paris, France, ⁵University of Würzburg, Würzburg, Germany, ⁶General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ⁷Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁸Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁹PMRGCAuk, London, United Kingdom, ¹⁰Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Westcliff-on-Sea, United Kingdom, ¹¹Rheumatology, Martina Hansens Hospital, Bærum, Oslo, Norway, ¹²Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ¹³Academic Rheumatology Unit, Università degli Studi di Torino, Torino, Italy, ¹⁴PMRGCAuk, Dundee, United Kingdom, ¹⁵Instituto de Medicina Molecular (IMM), Rheumatology Research Unit, Lisbon, Portugal, ¹⁶Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS; Università di Modena e Reggio Emilia, Reggio-Emilia, Italy, ¹⁷University of Groningen, Enschede, Netherlands, ¹⁸Southend University Hospital, Southend, United Kingdom, ¹⁹Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: Modern imaging modalities including ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) and 18F-FDG positron emission tomography (PET/CT) have been increasingly used in primary…
Abstract Number: 784 • 2017 ACR/ARHP Annual Meeting
Damage and Predictors of Damage in Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Kenneth J. Warrington¹³, Steven R. Ytterberg¹³ and Peter A. Merkel^1,14, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of California, Los Angeles, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Information regarding the degree and the predictors of damage in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to characterize damage and…
Abstract Number: 785 • 2017 ACR/ARHP Annual Meeting
Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis
Antoine G. Sreih¹, Tanaz A. Kermani², David Cuthbertson³, Simon Carette⁴, Lindsy J. Forbess⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux¹¹, Philip Seo¹², Robert F. Spiera¹³, Kenneth J. Warrington¹⁴, Steven R. Ytterberg¹⁴, Carol A. Langford¹⁵ and Peter A. Merkel^16,17, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of California, Los Angeles, CA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁶Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose : Longitudinal data on the type, progression, and predictors of arterial lesions in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to…
Abstract Number: 786 • 2017 ACR/ARHP Annual Meeting
Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
David Brennan¹, Patompong Ungprasert², Kenneth J. Warrington² and Matthew J. Koster², ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Tobacco smoking is a well-established risk factor for the development of several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. A similar…
Abstract Number: 787 • 2017 ACR/ARHP Annual Meeting
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
Alexandra Addario¹, Quitterie Reynaud^2,3, Maxime Samson⁴, Mathilde Francois³, Stéphane Durupt³, Francois Gueyffier¹, Michel Cucherat¹, Isabelle Durieu^2,5 and Jean-Christophe Lega^3,6, ¹Equipe Evaluation et Modélisation des Effets thérapeutiques, Lyon 1 University, Lyon, France, ²HESPER group, Lyon 1 University, Lyon, France, ³Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁴Department of Internal Medicine and Clinical Immunolgy, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Department of Internal and Vascular, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁶Equipe Evaluation et Modélisation des Effets thérapeutiques, UMR CNR 5558, Lyon 1 University, Lyon, France
Background/Purpose: The relapse rate of giant cell arteritis (GCA) in the patients treated by corticosteroids (CS) varied widely in observational series and randomized trials. The…
Abstract Number: 788 • 2017 ACR/ARHP Annual Meeting
Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis
Mingcai Zhang¹, Mehrdad Maz², Don Smith³, Noriko Miura⁴, Naohito Ohno⁵, Kottarappat Dileepan⁶ and Jason Springer⁷, ¹Department of Orthopedics, University of Kansas Medical Center, Kansas City, KS, ²Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan, ⁵Tokyo University of Pharmacy and Lift Sciences, Tokyo, Japan, ⁶Department of Medicine, University of Kansas Medical Center, Kansas, KS, ⁷Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS
Background/Purpose: In forms of large vessel vasculitis (LVV) systemic IL-6 has been shown to follow disease activity. Furthermore, IL-6 inhibition is an effective treatment for…
Abstract Number: 789 • 2017 ACR/ARHP Annual Meeting
Markers of Inflammation and Patient-Reported Measures As Predictors of Relapse in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine G. Sreih², Gunnar Tomasson³, David Cuthbertson⁴, Renee Borchin⁵, Simon Carette⁶, Lindsy J. Forbess⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux⁶, Philip Seo¹³, Robert F. Spiera¹⁴, Kenneth J. Warrington¹⁵, Steven R. Ytterberg¹⁵, Carol A. Langford¹⁶ and Peter A. Merkel^17,18, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Iceland, Faculty of Medicine, Reykjavik, IS, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵University of South Florida, Tampa, FL, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Medicine, Johns Hopkins University, Baltimore, MD, ¹⁴Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The significance of increasing erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in clinically asymptomatic individuals with giant cell arteritis (GCA) is controversial. Patient-reported…
Abstract Number: 790 • 2017 ACR/ARHP Annual Meeting
Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
Stefania Croci¹, Martina Bonacini¹, Francesco Muratore^2,3, Andrea Caruso³, Antonio Fontana⁴, Luigi Boiardi³, Alessandra Soriano^3,5, Alberto Cavazza⁶, Luca Cimino⁷, Lucia Belloni¹, Maria Parmeggiani¹, Miri Blank^8,9, Yehuda Shoenfeld^8,9 and Carlo Salvarani^2,3, ¹Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ²University of Modena and Reggio Emilia, Italy, Modena, Italy, ³Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁴Unit of Vascular Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁵Campus Bio-Medico, University of Rome, Italy, Roma, Italy, ⁶Unit of Pathology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁷Unit of Ocular Immunology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁸Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Ramat-Gan, Israel, ⁹Sackler Faculty of Medicine, Tel-Aviv University, Israel, Tel-Aviv, Israel
Background/Purpose: Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific molecule which has shown immunomodulatory effects in experimental mouse models of lupus, colitis and arthritis but data in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].